Tvardi Therapeutics Stock (NASDAQ:TVRD)
Previous Close
$3.74
52W Range
$3.50 - $43.65
50D Avg
$4.12
200D Avg
$17.80
Market Cap
$36.12M
Avg Vol (3M)
$101.02K
Beta
0.14
Div Yield
-
TVRD Company Profile
Tvardi Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. Their lead candidate, TTI-101, is currently in Phase 2 clinical trials for idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma (HCC).